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Abstract
The macrocyclic lactone ivermectin (Mectizan®) is widely used for the control of human filarial
infections, particularly as a donated product for onchocerciasis and lymphatic filariasis. In the case
of control of lymphatic filariasis in Africa, it is used in combination with donated albendazole. In
areas co-endemic for Onchocerciasis and Loa loa, serious adverse reactions have been observed in
patients with apparently high microfilaria counts of Loa loa. Recent findings suggest that the severe
central nervous system side effects seen in various vertebrates following ivermectin treatment may
be due to an absence of, or functional deficiency in P-glycoprotein. P-glycoprotein is expressed in
the apical membrane of brain capillary epithelial cells and is responsible for limiting the brain
penetration of a range of compounds. Toxicity of ivermectin in some collie dogs may be explained
by a 4-bp deletion mutation of the mdr1 gene resulting in a frame shift, generating stop codons that
prematurely terminate synthesis of P-glycoprotein. Additionally, sub-populations of CF-1 identified
as expressing reduced levels of P-glycoprotein exhibit increased toxicity to substrates of this
transporter. Furthermore, while the traditional view of drug-drug interactions is alteration in drug
clearance mediated through a change in hepatic drug metabolism, some of these changes may arise
through competition for binding sites on P-glycoprotein in the blood-brain barrier, resulting in
reduced extracellular efflux and enhanced CNS toxicity. In conclusion, P-glycoprotein is an integral
component of the human blood brain barrier and plays a central role in limiting drug uptake into
the brain. Altered expression or function of p-glycoprotein could conceivably allow elevation of
brain concentrations of ivermectin and produce severe neurotoxicity. This might arise through a
genetic polymorphism in p-glycoprotein or co-administration of ivermectin with a drug or foodstuff
that might inhibit this efflux transporter.
Background
Although clinical and veterinary usage of the broad-spec-
trum anthelmintic agent ivermectin has generally been
free of serious adverse events since 1991, a number of
clinical cases with and without neurological manifesta-
tions, including coma lasting 2–3 days, have been
reported after ivermectin treatment of individuals infected
with Onchocerca volvulus who also had concomitant Loa
loa infection with a high levels of microfilariae, typically >
30,000 microfilariae /ml of blood [1,2]. Although a cause
and effect relationship has yet to be established, it is
advised that individuals who warrant treatment with iver-
mectin for any reason and have had significant exposure
to Loa loa-endemic areas of West and Central Africa, pre-
from Report of a Scientific Working Group on Serious Adverse Events following Mectizan® treatment of onchocerciasis in Loa loa endemic areas 
Shrigley Hall Hotel, Manchester, UK, 28 – 30 May 2002
Published: 24 October 2003
Filaria Journal 2003, 2(Suppl 1):S8
This article is available from: http://filariajournal.com/content/2/S1/S8Filaria Journal 2003, 2(Suppl 1) http://filariajournal.com/content/2/S1/S8
Page 2 of 6
(page number not for citation purposes)
treatment assessment for loaiasis and careful post-treat-
ment follow-up should be implemented. The aim of this
brief review is to assess whether any of these events could
be attributed to the pharmacology of ivermectin, notably
its affinity for the P-glycoprotein drug transporter, which
might serve to reduce oral bioavailability of ivermectin
and prevent its uptake into the brain, thereby preventing
potentially fatal neurotoxicity.
Chemistry and Pharmacology of the Macrocyclic Lactones
The macrocyclic lactones comprise the avermectins (e.g.
doramectin and ivermectin; [Figure 1]) and the milbemy-
cins (e.g. moxidectin). They are natural fermentation
products of Streptomycetes  bacteria. Many have potent
anthelmintic and insecticidal properties [3,4] and are
drugs of choice for nematode infections in animals. Iver-
mectin is the preferred treatment for onchocerciasis and
other human filarial infections, such as Wuchereria ban-
crofti. Macrocyclic lactones produce a flaccid paralysis of
the somatic worm musculature and inhibit feeding of the
parasite through blockade of pharyngeal pumping [5–7],
suggesting that a disruption of ingestion is the primary
action of these agents [8] However, the somatic muscula-
ture is also understood to be a target and may explain the
reduction in release of uterine microfilariae seen after
exposure to ivermectin. Molecular genetics with C elegans
and expressed receptors has shown that macrocyclic lac-
tones act as agonists of a family of invertebrate-specific
inhibitory chloride channels that are activated by
glutamic acid [8–11] and related phylogenetically to ver-
tebrate GABAA gated chloride channels [12]. While the
selective effect of ivermectin can be explained by its action
on the glutamate-gated chloride channels unique to inver-
tebrates, at higher concentrations ivermectin can also
potentiate vertebrate GABAA gated chloride channels. This
has led to suggestions that ivermectin and related drugs
may be toxic in vertebrates having a deficiency in their
blood brain barrier [13]. Recent findings suggest that the
severe central nervous system side effects seen in various
vertebrates following ivermectin treatment may be due to
an absence of, or functional deficiency of P-glycoprotein
[14].
The Blood Brain Barrier and p-glycoprotein
The blood brain barrier is comprised of brain capillary
endothelial cells linked by tight junctions that form a
lipophilic physical barrier that limits the passive transport
of substances into the brain. While the permeability of the
Chemical structure of ivermectin Figure 1
Chemical structure of ivermectin. Ivermectin contains not less than 93.0% of 22,23 dihydroavermectin B1a (R = CH3) and the 
sum of B1a and B1b (R = C2H5) is not less than 97.0%. B1a, and not less than 97.0% of 22,23-dihydroavermectin B1 (B1a + B1b).Filaria Journal 2003, 2(Suppl 1) http://filariajournal.com/content/2/S1/S8
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blood brain barrier increases with increasing lipophilicity,
several transport proteins have been identified that regu-
late the penetration of many poorly lipophilic
compounds. Conversely, many highly lipophilic sub-
stances such as cyclosporin and ivermectin show unex-
pectedly poor penetration of the blood brain barrier. It is
now believed that this phenomenon is a result of the
actions of drug efflux transporters [15,16]. Although
molecular characterisation of those transport proteins
present in the apical and basolateral membrane of brain
capillary epithelial cells has identified a range of drug
transporters such as MDR, MRP and OATP [17–20], it is
p-glycoprotein that has been most widely studied. P-glyc-
oprotein is expressed in the apical membrane of brain
capillary epithelial cells and is orientated to pump nox-
ious substrates from inside cells and back into the blood
(Figure 2). P-glycoprotein is responsible for limiting the
brain penetration of a range of compounds of different
therapeutic classes and in some cases may influence deci-
sions regarding the clinical usage of such agents. For
example, the anti-diarrhoeal opiate loperamide is safe and
effective peripherally but does not act centrally since brain
penetration is minimised through the actions of p-glyco-
protein. However, it must be conceded that an accurate
Simplified cartoon of P-glycoprotein structure and function: The P-glycoprotein molecule spans the cell membrane and in this  way is in contact not only with the membrane but also the inside and the outside of the cell Figure 2
Simplified cartoon of P-glycoprotein structure and function: The P-glycoprotein molecule spans the cell membrane and in this 
way is in contact not only with the membrane but also the inside and the outside of the cell. The central portion of the mole-
cule is a channel or pore through which toxic chemicals are pumped back out into the environment. The toxic chemicals can 
enter the transport pore either from the interior of the cell or from its membrane as shown. Molecules of ATP power the 
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assessment of the role of p-glycoprotein in the function of
the human blood brain barrier is limited by our inability
to measure readily drug concentrations in the brain. Fur-
thermore, altered distribution within the brain may not
always show itself as a change in circulating plasma con-
centrations. [16]. A pharmacodynamic indicator would be
necessary to determine whether there was any exacerba-
tion of centrally mediated effects brought about through
genetic polymorphism in mdr1 [21,22] or inhibition of p-
glycoprotein function.
Neurotoxicology of Ivermectin
The principal toxicological effects of ivermectin seen in
rats are ataxia, ptosis and decreased activity, and in dogs
are mydriasis, tremors, ataxia and anorexia [23] with
enhanced sensitivity in infant rats that have a poorly
developed blood brain barrier (with regard to their defi-
ciency in p-glycoprotein), and show higher brain plasma
drug concentration ratios than adult rats. During the
development of Mectizan® two reports, one from the vet-
erinary use of ivermectin and another from a pre-clinical
toxicology study, influenced the clinical development of
Mectizan® such that a more conservative approach was
taken [24]. First, it was noticed that a sub-population of
collie dogs was remarkably sensitive to ivermectin-
induced neurotoxicity [25]. This occurs at doses that are 1/
200th of the dose required to cause toxicity in other dogs.
Neurological manifestations of ivermectin in susceptible
dogs include, hypersalivation, ataxia, blindness, coma,
respiratory compromise, and death. It is now known that
such ivermectin-sensitive collies exhibit a 4-bp deletion
mutation of the mdr1 gene that results in a frame shift,
generating several stop codons that prematurely terminate
synthesis of P-glycoprotein. Dogs that are homozygous
for the mutation display the ivermectin sensitive pheno-
type, whereas those homozygous normal or heterozygous
show no increased sensitivity to ivermectin [26]. Second,
sub populations of CF-1 mice were identified as express-
ing reduced levels of P-glycoprotein, including a popula-
tion that does not produce P-glycoprotein, identified as (-
/-) [27]. Animals with the wild type (+/+) or deficient gen-
otypes differ markedly in their sensitivity to ivermectin
neurotoxicity and teratology, attributable to differential
accumulation of ivermectin in brain and foetus. CF1 p-
glycoprotein deficient mice are phenoptypically identical
to mdr1a and mdr1b knockout strains established in the
laboratory [28]. Using such strains, differences in pharma-
cokinetics and tissue distribution, particularly accumula-
tion in the brain, of several substances can be
demonstrated when compared with p-glycoprotein wild
type mice [29,30]. These authors clearly established the
mdr1a transporter as central to limiting the oral bioavail-
ability and brain uptake of these agents. Studies with iver-
mectin and the p-glycoprotein substrate cyclosporin A in
CF-1 mice demonstrated enhanced absorption of iver-
mectin and cyclosporin A in the (-/-) strain although there
were no differences in the intravenous pharmacokinetics
of either drug. Hepatic drug metabolising capacity of (-/-)
and (+/+) animals was similar. Concentrations of [3H]-
ivermectin and [3H]-cyclosporin A were always higher in
the brains of (-/-) mice after oral or intravenous adminis-
tration but liver concentrations were identical to wild-type
mice. These findings clearly demonstrate that changes in
ivermectin disposition observed in the (-/-) mice arise
through a deficiency in p-glycoprotein rather than any
alteration in drug metabolism [14].
Drug-drug Interactions and Neurotoxicity of Ivermectin
Drug-drug interactions of clinical importance can occur
when the pharmacology of a drug is altered by co-admin-
istration of another agent. The question of drug-drug
interactions among anthelmintics is yet to be answered
satisfactorily. This is an important issue, since combina-
tion chemotherapy is becoming more widespread as
resistance to antiparasitic agents increases. For example
albendazole and ivermectin are co-administered in pro-
grammes to eliminate lymphatic filariasis [31]. Experi-
ments in human liver microsomes and recombinant
enzyme systems have shown that ivermectin and albenda-
zole are both substrates of cytochrome P450 (CYP) 3A4,
the most widely distributed human P-450, which is
expressed both in the liver and small intestine [32,33]. We
have shown that albendazole is converted to albendazole
sulphoxide, the major plasma metabolite in man, by
microsomes prepared from human intestinal tissue [34].
There is, therefore, the potential for drug-drug interactions
at each of these sites through competition for drug metab-
olising enzymes. The traditional view is that drug-drug
interactions are a result of alterations in drug clearance
mediated through a change in hepatic drug metabolism.
However, it is becoming clear that some of these changes
may arise through competition for binding sites on
transport proteins. Fluorescent-labelled ivermectin (BOD-
IPY-ivermectin) is extruded out of brain capillaries by a
concentrative mechanism and this export process is
reduced by substrates of p-glycoprotein without any
change in drug uptake [35]. Moreover, transport of BOD-
IPY-ivermectin is restricted to p-glycoprotein, as it is unaf-
fected by specific inhibitors of related transport proteins
and it interacts specifically with p-glycoprotein in func-
tional kidney tubules [36]. These findings suggest that
other P-glycoprotein substrates could compete with iver-
mectin at this site, resulting in reduced extracellular efflux
and enhanced CNS toxicity. Such compounds include
cyclosporin and HIV protease inhibitors [37,38].
Increased ivermectin concentrations accompanied by
enhanced neurotoxicity of ivermectin in mice has already
been demonstrated in the presence of cyclosporin [39].
While an interaction between ivermectin and albendazole
could be postulated on the basis of these drugs being coFilaria Journal 2003, 2(Suppl 1) http://filariajournal.com/content/2/S1/S8
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substrates of CY3A4, it is not established that there could
be an interaction at the level of p-glycoprotein. Although
ivermectin is undeniably a substrate for P-glycoprotein,
there is conflicting evidence for albendazole. Intestinal
metabolism and secretion of albendazole sulphoxide into
the intestinal lumen has been demonstrated and p-glyco-
protein is reported to be involved in modulating resist-
ance to albendazole in helminths [40,41]. However,
experiments in Caco-2 cells failed to identify albendazole
as a p-glycoprotein substrate or an inhibitor of p-glyco-
protein mediated transport of digoxin [42], suggesting
that a combination of the two drugs would not produce
an adverse drug reaction based upon an interaction with
p-glycoprotein. Albendazole sulphoxide or sulphone were
not investigated.
Conclusions
P-glycoprotein is an integral component of the human
blood brain barrier and plays a central role in limiting
drug uptake into the brain. Altered expression or function
of p-glycoprotein could conceivably allow elevation of
brain concentrations of ivermectin and produce severe
neurotoxicity. This might arise through a genetic poly-
morphism in p-glycoprotein or co-administration of iver-
mectin with a drug or foodstuff that might inhibit this
efflux transporter. There are relatively few examples of
clinically important drug-drug interactions at the blood-
brain barrier that involve increased drug exposure within
the brain. As mentioned previously, alterations in uptake
into the brain may not be manifest as a change in systemic
pharmacokinetics and may only become apparent when a
pharmacodynamic assessment is made [16]. Furthermore,
it may not be possible, with therapeutic doses, to achieve
sufficiently high concentrations of a co-substrate to allow
a drug-drug interaction to take place. For example, a range
of antipsychotic, antiemetic and Ca2+  blocking agents
failed to produce effective inhibition of p-glycoprotein
despite the achievement of suitable concentrations within
the systemic circulation [43]. Perhaps more importantly,
it should be remembered that clinical and laboratory find-
ings suggest that Mectizan®-associated L. loa encephalopa-
thy is consistent with an embolic process triggered by
massive microfilarial death. It may also involve circulating
immune complexes or polymorphic inflammatory
responses. Moreover, serious or even fatal encephalopa-
thy may develop spontaneously, or following treatment
with other microfilaricides such as diethylcarbamazine
[44]. It is therefore questionable whether any of the neu-
rological sequelae associated with administration of iver-
mectin are directly related to the drug and therefore it
seems unlikely that any alterations in the pharmacokinet-
ics of ivermectin for whatever reason would result in a
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